Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...

Warren Buffett says that if he were to start again, he’d look for old-fashioned value stocks. Stephen Wright thinks there’s an unusual one on offer. The post Why I’m considering considering breaking ...

The Golden Eagles (34-13 overall, 17-6 Sun Belt) won their eighth-straight contest as they tossed their third shutout of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago. These ...

Investors in Keros Therapeutics, Inc. KROS need to pay close attention to the stock based on moves in the options market lately. That is because the May 16, 2025 $70.00 Call had some of the highest ...

2-Year U.S. Treasury Note Continuous Contract $103.668-0.066-0.06% 5-Year U.S. Treasury Note Continuous Contract $108.367-0.156-0.14% 10-Year U.S. Treasury Note Continuous Contract $111.156-0.156 ...

Apr. 30, 2025 — Reduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Surprisingly ...